BCL2L1 and primary biliary cholangitis: The Bcl‐xL inhibitor A‐1331852 selectively eliminated senescent cholangiocytes and activated HSCs, reducing fibrosis, consistent with murine PSC and PBC studies [9, 18] (Figure 5).